Clinical trials: Acute Myeloid Leukemia
Acute Myeloid Leukemia
Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years
The purpose of this study is to determine whether the escalation dosage of Daunorubicin and cytarabine is effective and safety in the treatment of older adult Chinese acute myeloid leukemia（AML） patients aged 55 to 65 years.
- Trial name
- NCT02432872
- Testing
- Daunorubicin, Cytarabine
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Jianxiang Wang
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloblastic Leukemia
Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft
This is a preclinical study prior to the establishment of a cell therapy protocol applicable to humans. The main objective is to evaluate the decrease in alloreactivity of TCD4 + population by partial selective depletion of CD4 +…
- Trial name
- CCR7-CD4-DPL (NCT03280290)
- Testing
- blood
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Lille
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation.
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MDS/MPN)
- Trial name
- NCT04639024
- Testing
- ADCT-301
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gwynn Long, M.D.
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
The purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD).
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT01119066
- Testing
- total body irradiation, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 422 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myelodysplastic Syndromes
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
RATIONALE: Combinations of biological substances in DT388IL3 fusion protein may be able to carry cancer killing substances directly to the cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT00397579
- Testing
- DT388IL3
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Texas Southwestern Medical Center
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute
Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia
The purpose of this study is to determine whether a novel standard of care protocol, washing red cell and platelet transfusions for younger patients with acute leukemia, has yielded improved clinical outcomes at Strong Memorial…
- Trial name
- NCT01976442
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Rochester
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
The purpose of this study was to evaluate the safety and tolerability and to determine the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) of ASP7517.
- Trial name
- NCT04079296
- Testing
- ASP7517
- Where
- 16 sites in United States, Japan
- Volunteers
- 43 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- MYELO-CAN:TXA (NCT06599762)
- Testing
- Tranexamic acid
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University of Manitoba
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts.
- Trial name
- NCT02712905
- Testing
- INCB059872, all-trans retinoic acid (ATRA), azacitidine
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 116 people
- Sponsor
- Incyte Corporation
Relapsed or Refractory Acute Myeloid Leukemia (AML)
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD)…
- Trial name
- NCT06660368
- Testing
- Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
- Trial name
- NCT04940468
- Testing
- Diet Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Acute Myeloid Leukemia
Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML
1. Detection of IDH2 mutations in AML patients to define it incidence and correlation with clinical characteristics, relapse-free and overall survival. 2.
- Trial name
- NCT03537560
- Where
- Taiwan
- Volunteers
- 334 people
- Sponsor
- Chang Gung Memorial Hospital
Acute Myeloid Leukemia (AML)
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.
- Trial name
- NCT05188170
- Testing
- Niclosamide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Stanford University
Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly
This is a prospective phase II, single-arm clinical study that plans to enroll 45 patients aged 60 years or older with primary AML diagnosed after April 1, 2023.The purpose of this trial is to evaluate the efficacy of Venetoclax…
- Trial name
- NCT05949762
- Testing
- Venetoclax in Combination With Azacitidine and HA Regimen
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- ZePing Zhou
AML/MDS
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
The aim of this study is to investigate how safe and effective the addition of the new medicine midostaurin to decitabine is for the treatment of unfit acute myeloid leukemia (AML) and high-risk myelodysplasia (MDS) patients.
- Trial name
- HO155 (NCT04097470)
- Testing
- Decitabine, Midostaurin
- Where
- 37 sites in Belgium, Germany and 2 more
- Volunteers
- 140 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Leukemia
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the transplanted stem cells.
- Trial name
- NCT00049517
- Testing
- sargramostim, busulfan, cyclophosphamide
- Where
- 99 sites in United States, Israel
- Volunteers
- 657 people
- Sponsor
- Eastern Cooperative Oncology Group
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person).
- Conditions
- For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML)
- Trial name
- NCT02200380
- Testing
- CDX-301, CDX-301 and plerixafor
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Acute Myeloid Leukemia
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia
- Trial name
- NCT06451861
- Testing
- Chidamide, Venetoclax, azacitidine
- Where
- 13 sites in China
- Volunteers
- 240 people
- Sponsor
- Guangdong Provincial People's Hospital
Leukemia
Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003868
- Testing
- cyclophosphamide, methotrexate, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center